{"abstract":"The Drug Enforcement Administration proposes to transfer suvorexant ([(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4- diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone), lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)- N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide), and daridorexant ([(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1- yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone) from schedule IV to schedule V of the Controlled Substances Act. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule V controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle suvorexant, lemborexant, and daridorexant.","action":"Notice of proposed rulemaking.","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2026/08/11/2026-16375.html","cfr_references":[{"chapter":null,"citation_url":null,"part":"1308","title":21}],"citation":"91 FR 51606","comment_url":null,"comments_close_on":"2026-09-10","correction_of":null,"corrections":[],"dates":"Comments must be submitted electronically or postmarked on or before September 10, 2026. The electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period.","disposition_notes":null,"docket_ids":["Docket No. DEA-1645"],"dockets":[{"supporting_documents":[{"title":"OASH to DEA Letter DORAs 8FA Dec2025","document_id":"DEA-2026-1321-0004"},{"title":"DEA 8 Factor DORAs May2026","document_id":"DEA-2026-1321-0003"},{"title":"OASH to DEA 8FA Full Report DORAs Dec2025","document_id":"DEA-2026-1321-0002"}],"agency_name":"DEA","documents":[{"comment_count":19,"comment_start_date":"2026-08-11","updated_at":"2026-09-11T01:56:36.334-04:00","comment_url":"https://www.regulations.gov/commenton/DEA-2026-1321-0001","allow_late_comments":false,"id":"DEA-2026-1321-0001","comment_end_date":"2026-09-11","regulations_dot_gov_open_for_comment":false}],"supporting_documents_count":3,"id":"DEA-2026-1321","title":"Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant From Schedule IV Into Schedule V  (DEA1645)"}],"document_number":"2026-16375","effective_on":null,"end_page":51611,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2026/08/11/2026-16375.xml","html_url":"https://www.federalregister.gov/documents/2026/08/11/2026-16375/schedules-of-controlled-substances-rescheduling-of-suvorexant-lemborexant-and-daridorexant-from","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2026-16375?publication_date=2026-08-11","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2026-08-11/2026-16375/mods.xml","not_received_for_publication":null,"page_length":6,"page_views":{"count":1745,"last_updated":"2026-10-23 06:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-11/pdf/2026-16375.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16375.pdf?1786365921","publication_date":"2026-08-11","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2026/08/11/2026-16375.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[{"title":"OASH to DEA Letter DORAs 8FA Dec2025","document_id":"DEA-2026-1321-0004"},{"title":"DEA 8 Factor DORAs May2026","document_id":"DEA-2026-1321-0003"},{"title":"OASH to DEA 8FA Full Report DORAs Dec2025","document_id":"DEA-2026-1321-0002"}],"comments_count":19,"agency_id":"DEA","comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=DEA-2026-1321","supporting_documents_count":3,"docket_id":"DEA-2026-1321","document_id":"DEA-2026-1321-0001","regulation_id_number":null,"title":"Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant From Schedule IV Into Schedule V  (DEA1645)","checked_regulationsdotgov_at":"2026-09-12T08:55:04Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":51606,"subtype":null,"title":"Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant From Schedule IV Into Schedule V","toc_doc":"Rescheduling of Suvorexant, Lemborexant, and Daridorexant from Schedule IV into Schedule V","toc_subject":"Schedules of Controlled Substances","topics":["Administrative practice and procedure","Drug traffic control","Reporting and recordkeeping requirements"],"type":"Proposed Rule","volume":91}